• 제목/요약/키워드: Cessation of treatment

검색결과 182건 처리시간 0.026초

Current Status of Anti-HBV Chemotherapy

  • Hong, Joon H.;Choi, Yong-Seok;Chun, Byoung K.;Lee, Kyeong;Chu, Chung K.
    • Archives of Pharmacal Research
    • /
    • 제21권2호
    • /
    • pp.89-105
    • /
    • 1998
  • In the past decade, significant progress has been achieved in the battle against hepatitis B virus. In addition to the immunomodulating agents such as interferon-.alpha., and thymosin, many novel antiviral agents have been discovered, among which nucleoside analogues are the mainstay. New-generation compounds such as 3TC and famciclovir have shown promise in the treatment of patients chronically infected by this virus, and are on the line for approval. However, viral rebound after cessation of therapy still remains a major problem. Additionally, the reports on the drug resistance to these antiviral agents suggest that combination therapy will be the eventual strategy (Bartholomew et al., 1997; Tipples et al., 1996). Therefore, developments of safe and effective antiviral agents which do not cross-resist with currently available antiviral drugs are still much needed.

  • PDF

Focal Bone Marrow Lesions: A Complication of Ultrasound Diathermy

  • Kim, Seung Jae J.;Kang, Yusuhn;Kim, Dae Ha;Lim, Jae Young;Park, Joo Hyun;Oh, Joo Han
    • Clinics in Shoulder and Elbow
    • /
    • 제22권1호
    • /
    • pp.40-45
    • /
    • 2019
  • Ultrasound diathermy is widely used for the treatment of musculoskeletal disorders and other soft tissue injuries. Its use as a therapeutic modality is believed to be safe, with very few reported complications. Here, we report two patients who developed focal bone marrow abnormalities after receiving ultrasound diathermy. Both patients' magnetic resonance (MR) evaluations revealed linear subchondral bone lesions of the superolateral humeral head similar to those in osteonecrosis. The patients' symptoms subsequently improved, and available follow-up MR evaluation revealed near complete resolution of bone lesions. These findings suggest that ultrasound diathermy, and its interaction with bone tissue through thermal mechanisms, can cause focal bone marrow abnormalities. Furthermore, the bone marrow abnormalities seem to be transient, resolving upon cessation of ultrasound diathermy, therefore osteonecrosis should be differentiated from this temporal lesion.

Recombinant Human Erythropoietin(DA-3285)의 효력 및 일반약리작용 (Efficacy and General Pharmacology of Recombinant Human Erythropoietin(DA-3285))

  • 김동환;안병옥;손문호;신명수;이성희;김원배;양중익
    • Biomolecules & Therapeutics
    • /
    • 제4권1호
    • /
    • pp.68-77
    • /
    • 1996
  • Efficacy and general pharmacology of recombinant human erythropoietin (rHu-EPO), were investigated. Efficacy studies were conducted in normal, cisplatin- and acute hemorrhage-induced anemic rats. Normal and anemic animals were treated intravenously with rHu-EPO for 5 days and the changes in the numbers of red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct) and reticulocytes (Ret) were examined. In normal rats, rHu-EPO significantly increased RBC, Hb, Hct and Ret at doses of 50∼ 1250 IU/kg/day. Cisplatin-induced anemic rats showed significant increase of RBC, Hb, Hct and Ret in a dose-dependent manner after administration of rHu-EPO (50∼200 lU/kg/day). And in acute hemorrhage-induced anemic rats, rHu-EPO(4∼100 Iu/kg/day) accelerated recovery of anemia with significant increase in Ret. These changes disappeared gradually after cessation of the treatment. The general pharmacological effects of rHu-EPO were investigated in mice, rats, guinea-pigs, rabbits and cats. rHu-EPO had no influences on central nervous, cardiovascular, gastrointestinal and blood coagulation system. It also had no influence on the contraction of phrenic nerve-diaphragm preparation. rHu-EPO produced significant increase of urine volume at a dose of 7000 IU/kg. These results suggest that rHu-EPO might be useful for the therapy of anemia without serious side effect.

  • PDF

Nasolabial and extended nasolabial flaps for reconstruction in oral submucous fibrosis

  • Qayyum, Muhammad Umar;Janjua, Omer Sefvan;Haq, Ehtesham Ul;Zahra, Rubbab
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • 제44권4호
    • /
    • pp.191-197
    • /
    • 2018
  • Objectives: The objective of the study was to evaluate the results of nasolabial/extended nasolabial flaps as a modality for treatment of oral submucous fibrosis. Materials and Methods: Eleven patients of Stage III or IVa maximum interincisal opening were selected to be operated. Nasolabial/extended nasolabial flaps were done for both the sides. All of the flaps were done in a single stage and were inferiorly based. A similar flap harvest/surgical technique was utilized for all the cases. Results: The preoperative mouth opening ranged from 5 to 16 mm, with a mean of 10.09 mm. At 6 months the mouth opening ranged from 29 to 39 mm. Some of the complications encountered were poor scar, wisdom tooth traumatising the flap, decreased mouth opening due to non compliance and too much bulk. All of theses were managed satisfactorily. Conclusion: The nasolabial flap is a very reliable flap to restore the function of oral cavity. Important adjuvant measures are habit cessation, lifestyle changes, and aggressive physiotherapy.

문헌고찰을 통한 근로자의 대사증후군 관리방안 제시 (The Management Strategies of Metabolic Syndrome among Workers through the Literature Review)

  • 최은숙;전경자
    • 한국직업건강간호학회지
    • /
    • 제14권2호
    • /
    • pp.138-152
    • /
    • 2005
  • Purposes: The purposes of this study are to investigate the definition, components, prevalence, and associated factors of metabolic syndrome and suggest the management strategies for workers. Method: This study was conducted by literature review. Results: Metabolic syndrome by the NCEP-ATP III is the clustering of three or more of five conditions: abdominal obesity, high triglycerides, low levels of HDL cholesterol, high blood pressure, and high glucose(blood sugar). The prevalence of the metabolic syndrome by modified NCEP-ATP III in South Korean workers was about 20 to 25%. Metabolic syndrome is caused by many associated factors, namely, age, family history, socioeconomic status, job strain, shift work, psychosocial distress, bad health behaviprs and so on. Conclusions: To prevent metabolic syndrome at worksites, multifactorial risk factor assessments and preventive approaches are required. Socioeconomic factors such as education, working status should be nationally importantly considered for the health inequality of workers. Occupational health nurse, at first, can start weight control, smoking cessation program. stress management, the improvement of work environment. Next stage, early diagnosis and treatment for metabolic risk group can be performed.

  • PDF

Clinical Problems in ML II and III: Extra-skeletal Manifestations

  • Park, Sung Won
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제2권1호
    • /
    • pp.5-7
    • /
    • 2016
  • Mucolipidoses II and III alpha/beta (ML II and ML III) are lysosomal disorders in which the essential mannose-6-phosphate recognition marker is not synthesized onto lysosomal hydrolases and other glycoproteins. The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase ML II, recognizable at birth, often causes intrauterine growth impairment and sometimes the prenatal "Pacman" dysplasia. The main postnatal manifestations of ML II include gradual coarsening of neonatally evident craniofacial features, early cessation of statural growth and neuromotor development, dysostosis multiplex and major morbidity by hardening of soft connective tissue about the joints and in the cardiac valves. Fatal outcome occurs often before or in early childhood. ML III with clinical onset rarely detectable before three years of age, progresses slowly with gradual coarsening of the facial features, growth deficiency, dysostosis multiplex, restriction of movement in all joints before or from adolescence, painful gait impairment by prominent hip disease. Cognitive handicap remains minor or absent even in the adult, often wheelchair-bound patient with variable though significantly reduced life expectancy. As yet, there is no cure for individuals affected by these diseases. So, clinical manifestations and conservative treatment is important. This review aimed to highlight the extra-skeletal clinical problems in ML II and III.

Obesity and Metabolic Syndrome in Adults with Prader-Willi Syndrome

  • Kim, Su Jin
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제1권2호
    • /
    • pp.44-48
    • /
    • 2015
  • Body fat distribution in patients with Prader-Willi syndrome (PWS) is characterized by reduce lean body mass (LBM), increased total body fat mass (FM), and lower percentage of visceral adipose tissue (VAT). Individuals with PWS seem to have a lower risk for insulin resistance with high levels of adiponectin, an anti-atherogenic adipocytokine that is decreased in visceral fat hypertrophy subjects compared to simple obese subjects, both in children and in adults. The mechanism of the reduction in visceral adiposity in PWS is still unclear. It might be related to qualitative intrinsic characteristics of adipocyte or novel genetic influences on the control of fat distribution. However, obesity remains a critical problem, and obesity status plays a crucial role in individual metabolic risk clustering and development of metabolic syndrome (Mets) in PWS children and adults. Long-term growth hormone (GH) treatment after cessation of skeletal growth improved body composition, with an increase in lean body mass and a reduction in total body fat and subcutaneous and visceral fat in PWS adults. Thus, the role of GH is important after childhood because it might attenuate obesity and Mets in PWS adult by adipocyte modification.

폐경과 수면 (Sleep in Menopause)

  • 임원정
    • 수면정신생리
    • /
    • 제9권2호
    • /
    • pp.96-99
    • /
    • 2002
  • Menopause, the cessation of menstruation caused by the decline in estrogen production, occurs in 95% of women between 40 and 60 years. Sleep disturbance is a frequent complaint during the perimenopause period. In contrast to premenopausla women, menopausal women experience more reduction in the total sleep hours and report more sleep disturbances, such as insomnia, noctiria and sleep disordered breathing. But the prevalence, etiology and treatment of sleep disturbances in menopause are still controversal. So further investigations are required to elucidate the factors that account for the differences in sleep disturbance between premenopausal and postmenopausal women. There are suggestive data that estrogen and progesterone deficiency may increase the susceptibility for sleep disorder in menopause. Furthermore, there are suggestive evidence from observational studies and a limited number of randomized, controlled trials that hormone replacement therapy after menopause improves sleep. However, the clinical relevance of hormone replacement therapy is unproved. So the overall benefit of hormonal replacement in postmenopausal women with sleep related disorders should be individualized to avoid potential side effects. Several studies evaluated the role of melatonin, because this hormone has effects on core body temperature & insomnia. But the exact dosage and the effects of long-term use of melatonin are unclear. So, caution is indicated in melatonin administration.

  • PDF

Silver Diamine Fluoride Compound for Dental Caries and Its Characterisation Using Microscopic Computed Tomography and Nanoindentation

  • So-Youn An;Myung-Jin Lee;Min-Kyung Kang;Youn-Soo Shim
    • 치위생과학회지
    • /
    • 제23권1호
    • /
    • pp.60-67
    • /
    • 2023
  • Background: In our study, a silver diamine fluoride (SDF) compound for the treatment of dental caries was synthesized to characterize its remineralization activity upon direct application to deciduous teeth. This study aimed to use microscopic computed tomography (microCT) and nanoindentation to evaluate whether SDF composite application could effectively arrest dental caries in five exfoliated primary molars. Methods: Carious teeth were extracted and visually examined using quantitative photofluorescence devices (Qraycam and QraypenTM). After performing microCT, the SDF composite was applied to the teeth according to the manufacturer's instructions. The researchers exchanged and precipitated the irritant saliva once daily for 1 week. The teeth were sectioned longitudinally through the centers of the mesial and distal surfaces, embedded, polished, and measured using nanoindentation. Thereafter, microCT was repeated. Statistical analyses were performed using GraphPad Prism software. Results: Following SDF composite application, a remineralized layer was observed on microCT images, and the hardness increased when measured using nanoindentation. We found that demineralized enamel presented with an increased number of irregular crystals in the deep carious lesion group compared with those in the shallow carious lesion group, resulting in a rougher surface. Conclusion: The SDF composite may be used for remineralization of early caries and cessation of advanced caries in primary molars.

Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction

  • Oh, Dongryul;Park, Hee Chul;Lim, Ho Yeong;Yoo, Byung Chul
    • Radiation Oncology Journal
    • /
    • 제31권3호
    • /
    • pp.171-174
    • /
    • 2013
  • Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been reported so far. Our patient with recurrent HCC was treated with palliative radiotherapy (RT) for the chest wall mass. Sorafenib at 400 mg twice daily was begun on the day following RT. On the 14th day post-RT, an erythematous patch was observed on right chest wall which matched area previously irradiated. It was consistent with RRD. Ten days later, a disseminated exanthematous rash and severe pruritus occurred. Sorafenib was stopped and an oral antihistamine was prescribed to relieve symptoms. At the 1-week follow-up after the cessation of sorafenib, all symptoms were resolved. Physicians should be alert to this recall phenomenon as it can occur both in the skin and elsewhere and the occurrence of RRD may be unpredictable.